BioSpace News Archive

According to the 5th Edition of the “State of the States Report,” released by the National Organization for Rare Disorders and its Rare Action Network, while many US states took powerful steps forward in 2019, there is major work yet to be done on a number of policy issues critical to over 25 million Americans affected by rare diseases.

Assay enables development of reliable molecular diagnostics for faster treatments and vaccines

Envista Holdings Corporation (NYSE: NVST) today announced results for the fourth quarter 2019

Concert Pharmaceuticals, Inc. announced the closing of its previously announced underwritten public offering of 5,735,283 shares of its common stock to the public at $9.92 per share, which included the full exercise of the underwriters’ option to purchase 982,863 additional shares of common stock.

- Results support ongoing Phase 1/2 AUGMENT-101 trial of Syndax Pharmaceuticals’ lead Menin-MLL inhibitor, SNDX-5613, for the treatment of adults with relapsed/refractory acute leukemias, including NPM1 mutant AML

OTTAWA , Jan. 30, 2020 /CNW/ - The Chief Public Health Officer, Dr. Theresa Tam , and the Deputy Chief Public Health Officer, Dr. Howard Njoo , will hold a media availability to provide an update on the novel coronavirus (referred to as 2019-nCoV).

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced that it intends to offer and sell shares of its common stock and, to certain investors in lieu thereof, pre-funded warrants to purchase shares of its common stock, in an underwritten public offering

Acacia Diversified Holdings, Inc. (“Acacia” or the “Company”) (OTCQB: ACCA), an emerging hemp Company, through its wholly owned subsidiaries, MariJ Pharmaceuticals, Inc. www.marijinc.com (MariJ), and Eufloria Medical of Tennessee, Inc. www.eufloriamedical.com

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2019 versus comparable periods in 2018.

Varex Imaging Corporation (Nasdaq: VREX) today announced it will showcase its updated 3D VSHARP software for industrial cone beam computed tomography (CBCT) at iCT2020.